Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Shionogi & Co ( (JP:4507) ).
Shionogi reported consolidated revenue of ¥360.7 billion for April–December FY2025, up 8.1% year on year, driven primarily by higher royalty income, growth in prescription drug sales, and contributions from overseas subsidiaries and exports, despite a decline in acute respiratory viral infection treatments. Operating profit rose 15.1% to ¥148.7 billion and profit attributable to owners of the parent increased 18.3% to ¥158.2 billion, supported by the consolidation of Torii Pharmaceutical, increased sales-related investment in the U.S., and higher dividends from its HIV partner ViiV, with core operating profit and EBITDA remaining broadly stable.
The most recent analyst rating on (JP:4507) stock is a Buy with a Yen3466.00 price target. To see the full list of analyst forecasts on Shionogi & Co stock, see the JP:4507 Stock Forecast page.
More about Shionogi & Co
Shionogi & Co., Ltd. is a Japanese pharmaceutical company focused on prescription drugs, including treatments for infectious diseases such as acute respiratory viral infections, HIV, and pain management products, as well as over-the-counter and quasi-drug offerings. The company also generates substantial royalty income, particularly from its HIV franchise, and has been expanding its presence through overseas subsidiaries in the U.S., Europe and China, alongside contract manufacturing operations.
Average Trading Volume: 2,929,620
Technical Sentiment Signal: Buy
Current Market Cap: Yen2770.5B
For a thorough assessment of 4507 stock, go to TipRanks’ Stock Analysis page.